KPC(SH:600422) Xin Lang Cai Jing·2025-09-10 05:27Group 1 - The core viewpoint of the news is that Kunming Pharmaceutical Group has experienced fluctuations in stock price and trading volume, with a recent increase of 2.04% on September 10, 2023, reaching a price of 14.51 yuan per share and a total market capitalization of 10.984 billion yuan [1] - The company has seen a net inflow of main funds amounting to 12.3974 million yuan, with significant buying from large orders totaling 32.9638 million yuan, indicating positive investor sentiment [1] - Year-to-date, the stock price has decreased by 6.69%, but it has increased by 3.05% over the last five trading days, suggesting some recovery in the short term [1] Group 2 - Kunming Pharmaceutical Group operates primarily in the pharmaceutical industry, with its main business segments including natural plant medicine (26.73%), chemical synthesis drugs and health products (4.26%), and pharmaceutical wholesale (34.45%) [1] - As of June 30, 2025, the company reported a revenue of 3.351 billion yuan, a year-on-year decrease of 5.71%, and a net profit attributable to shareholders of 198 million yuan, down 13.56% compared to the previous year [2] - The company has distributed a total of 1.928 billion yuan in dividends since its A-share listing, with 500 million yuan distributed in the last three years [3] Group 3 - As of June 30, 2025, the number of shareholders for Kunming Pharmaceutical Group increased by 7.26% to 39,400, while the average circulating shares per person decreased by 6.77% to 19,229 shares [2] - The top shareholders include various funds, with notable changes in holdings, such as a decrease of 10 million shares by the third-largest shareholder and an increase of 318,500 shares by the fourth-largest shareholder [3]